Wolverine Trading’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-11,100
| Closed | -$54.6K | – | 5368 |
|
|
2024
Q1 | $54.6K | Buy |
+11,100
| New | +$65.7K | ﹤0.01% | 4199 |
|
|
2023
Q4 | – | Sell |
-25,400
| Closed | -$291K | – | 5382 |
|
|
2023
Q3 | $291K | Sell |
25,400
-7,700
| -23% | -$148K | ﹤0.01% | 3323 |
|
|
2023
Q2 | $818K | Sell |
33,100
-400
| -1% | -$12.5K | ﹤0.01% | 2171 |
|
|
2023
Q1 | $1.04M | Sell |
33,500
-7,500
| -18% | -$234K | ﹤0.01% | 1862 |
|
|
2022
Q4 | $757K | Buy |
41,000
+6,000
| +17% | +$137K | ﹤0.01% | 2039 |
|
|
2022
Q3 | $898K | Buy |
+35,000
| New | +$710K | ﹤0.01% | 2069 |
|
|
2020
Q1 | – | Sell |
-15,900
| Closed | -$256K | – | 5450 |
|
|
2019
Q4 | $256K | Sell |
15,900
-1,300
| -8% | -$20.2K | ﹤0.01% | 3787 |
|
|
2019
Q3 | $237K | Sell |
17,200
-4,100
| -19% | -$50.2K | ﹤0.01% | 3403 |
|
|
2019
Q2 | $276K | Buy |
21,300
+9,500
| +81% | +$120K | ﹤0.01% | 3368 |
|
|
2019
Q1 | $186K | Sell |
11,800
-700
| -6% | -$12.1K | ﹤0.01% | 3879 |
|
|
2018
Q4 | $243K | Sell |
12,500
-5,300
| -30% | -$117K | ﹤0.01% | 3462 |
|
|
2018
Q3 | $442K | Buy |
17,800
+6,900
| +63% | +$188K | ﹤0.01% | 3261 |
|
|
2018
Q2 | $336K | Hold |
10,900
| – | – | ﹤0.01% | 3620 |
|
|
2018
Q1 | $336K | Sell |
10,900
-4,000
| -27% | -$129K | ﹤0.01% | 3620 |
|
|
2017
Q4 | $533K | Buy |
+14,900
| New | +$428K | ﹤0.01% | 2920 |
|
|
2017
Q3 | – | Sell |
-8,200
| Closed | -$215K | – | 5184 |
|
|
2017
Q2 | $215K | Buy |
+8,200
| New | +$183K | ﹤0.01% | 3507 |
|
Other funds holding RVNC
Wolverine Trading's RVNC Position: Q2 2024 in Review
Wolverine Trading sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2024, closing a stake of 13,931 shares — an estimated $47.6K sold.
Wolverine Trading first reported a position in RVNC in Q4 2017 and held it in 10 quarters. The position peaked at $692K in Q1 2023. 173 funds tracked by Wall St. Rank hold RVNC as of Q2 2024.
- Wolverine Trading reported no remaining Revance Therapeutics, Inc. position as of Q2 2024 after selling out during the quarter.
- Wolverine Trading sold 13,931 Revance Therapeutics, Inc. shares in Q2 2024, an estimated $47.6K.
- Wolverine Trading first reported a position in Revance Therapeutics, Inc. in Q4 2017 and held it in 10 quarters.
- Wolverine Trading's Revance Therapeutics, Inc. position peaked at $692K in Q1 2023.
- 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2024.
Based on Wolverine Trading's 13F filing for Q2 2024, filed 14 Aug 2024.